SCHEMBL4496231

SCHEMBL4496231

CCOC(=O)C1CCC(=O)N(C(CC)C(=O)OC(C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.41
MAPT P10636 3/20 0.41
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
HTT P42858 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
LMNA P02545 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4491631 0.85 LMNA (0.56) ALDH1A1TSHRSMN1; SMN2KDM4EMAPT
SCHEMBL4501049 0.85 KDM4E (0.47) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL4445759 0.79 LMNA (0.63) ALDH1A1KMT2ATSHRKDM4EMAPT
SCHEMBL563878 0.73 BRD4 (0.48) ALDH1A1KMT2ATSHRSMN1; SMN2MAPT
SCHEMBL563620 0.73 BRD4 (0.48) ALDH1A1KMT2ATSHRSMN1; SMN2MAPT
SCHEMBL6871751 0.73 ALDH1A1 (0.45) ALDH1A1MEN1KMT2ATSHRSMN1; SMN2
SCHEMBL10239660 0.73 MAPT (0.55) KMT2ATSHRSMN1; SMN2MAPTPOLB
SCHEMBL10239631 0.73 MAPT (0.41) KMT2ATSHRSMN1; SMN2MAPTPOLB
SCHEMBL10239641 0.72 MDM2 (0.33) ALDH1A1MEN1KMT2ATSHRMAPT
SCHEMBL13437755 0.72 MDM2 (0.33) ALDH1A1MEN1KMT2ATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040132717-A1 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB, S.A. (BE) 2004-07-08 US claimed
EP-1395560-A1 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS UCB, S.A. (BE) 2004-03-10 EP claimed
WO-2002094787-A1 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS UCB, S.A. (BE) 2002-11-28 WO claimed
US-7473697-B2 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB S.A. (BE) 2009-01-06 US disclosed
US-7473697-B2 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB S.A. (BE) 2009-01-06 US disclosed
US-7473697-B2 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB S.A. (BE) 2009-01-06 US disclosed
US-20060258704-A1 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders MICHEL PHILIPPE 2006-11-16 US disclosed
US-7087596-B2 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB, S.A. (BE) 2006-08-08 US disclosed
US-20040132717-A1 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB, S.A. (BE) 2004-07-08 US disclosed
EP-1395560-A1 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS UCB, S.A. (BE) 2004-03-10 EP disclosed
WO-2002094787-A1 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS UCB, S.A. (BE) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132717-A1 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders GABRA6, GABRA2, HCAR2 ALDH1A1 131/4885MEN1 3450/4885KMT2A 1040/4885
US-20060258704-A1 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders GABRA6, HCAR2, GABRA2 ALDH1A1 139/4885MEN1 3470/4885KMT2A 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.